RWE in an evolving regulatory landscape: Using real-world evidence to support novel product development pathways

November 13, 2019 Patty Collinsworth

The growing interest in RWE from both regulators and payors, along with innovative data models and technologies, has the potential to transform clinical research as we know it. Particularly for rare diseases, the opportunity to utilize existing data and to link patients across multiple datasets, in concert with proven prospective research models within non-traditional infrastructure settings, offers important opportunities both to streamline the research process and also to bring the needed real-world perspective and data to the table. Real-world data also can provide important information in the post-marketing setting, especially from a safety perspective, to answer regulatory questions.

Listen to this on-demand webinar with Parexel experts Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence and Amy McKee, M.D., Vice President, Regulatory Consulting Services to learn more about:

• The changing global regulatory perspective on RWE

• Utilizing RWE in synthetic control arms to support regulatory submissions

• Innovative approaches to accessing and integrating RWE today

To register, visit:

Previous Article
Biosimilars in China: Riding an upward trend
Biosimilars in China: Riding an upward trend

In February 2019, National Drug Regulators in China approved the country’s first ever biosimilar product re...

Next Flipbook
Cell and Gene Therapy & Tissue Engineering
Cell and Gene Therapy & Tissue Engineering


Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Tell us how we can help
Thank you!
Error - something went wrong!